Agios Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
57.99 M |
Public Float |
29.05 M |
Agios Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$5.99 |
Market Cap |
$2.69 B |
Shares Outstanding |
58.71 M |
Public Float |
50.88 M |
Address |
88 Sidney Street Cambridge Massachusetts 02139 United States |
Employees | - |
Website | http://www.agios.com |
Updated | 07/08/2019 |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270. |